|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
The study explores whether Ceramide NanoLiposome (CNL) combined with other conventional cancer-fighting drugs makes them work better.
Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
100 Clinical Results associated with PendreaBio Inc.
0 Patents (Medical) associated with PendreaBio Inc.
100 Deals associated with PendreaBio Inc.
100 Translational Medicine associated with PendreaBio Inc.